Soleno Therapeutics Inc.
Soleno Therapeutics Announces Performance-Based Stock Awards for Executives
Summary
On July 17, 2024, Soleno Therapeutics, Inc. announced that its Board of Directors, following the recommendation of the Compensation Committee, granted performance-based restricted stock units to its employees, including its named executive officers. The President and CEO, Anish Bhatnagar, was awarded 850,000 shares, while the Chief Financial Officer, James Mackaness, and Senior Vice President of Regulatory Affairs, Patricia Hirano, were awarded 100,000 and 85,000 shares, respectively. These grants aim to align employee equity with the company's peer group levels.
Profitelligence Alerts
Get alerts for SLNO
Be first to know when Soleno Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Soleno Therapeutics Inc.
Soleno Therapeutics Inc. is a biopharmaceutical company dedicated to the development and commercialization of novel therapeutics for rare diseases. Its primary focus lies on the treatment of genetic disorders that have a significant medical need, such as Prader-Willi syndrome, a complex condition that affects the musculoskeletal and endocrine systems. Soleno is committed to pioneering advancements in the pharmaceutical industry by leveraging innovative approaches to drug development. The company's lead treatment candidate, rooted in addressing metabolic and neurobehavioral abnormalities, plays a critical role within its pipeline. Soleno's research and development efforts are concentrated on improving patient outcomes through therapies that target underlying disease mechanisms. Based in Redwood City, California, Soleno Therapeutics Inc. actively collaborates with scientific communities and healthcare providers to enhance its therapeutic offerings. In the financial market, Soleno Therapeutics is notably positioned as part of the healthcare and biotechnology sectors, reflecting its significance in developing treatments that can transform patient care and address unmet medical needs in niche and complex disease areas.
Official SEC Documents
Advertisement